{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-23-000030","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.848098+00:00","generated_at":"2026-06-10T21:45:04.505837+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moderna and Immatics announce $120M upfront oncology collaboration for TCR bispecifics and cancer vaccines","bullets":["Immatics receives $120M upfront plus research funding; milestones could exceed $1.7B plus tiered royalties on net sales.","Collaboration spans three pillars: mRNA-expressed TCER bispecifics, novel mRNA cancer vaccines using XPRESIDENT, and IMA203 TCR-T combo with Moderna's PRAME vaccine.","Moderna leads clinical development and commercialization of TCER and vaccine products; Immatics handles preclinical/Phase 1 for the combo study.","Immatics holds option to enter global profit/loss share for the most advanced TCER program.","Deal subject to customary US antitrust clearance; Moderna retains full ownership of its PRAME compound."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-23-000030","json":"https://secwatch.observer/filing/0001682852-23-000030.json","markdown":"https://secwatch.observer/filing/0001682852-23-000030.md","text":"https://secwatch.observer/filing/0001682852-23-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000030/0001682852-23-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000030/mrna-20230911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:45:04.505837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}